Put companies on watchlist
MEDIQON Group AG
ISIN: DE0006618309
WKN: 661830
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

MEDIQON Group AG · ISIN: DE0006618309 · EQS - Company News (50 News)
Country: Germany · Primary market: Germany · EQS NID: 1642503
26 May 2023 08:55AM

MEDIQON Group AG: Expansion of Capital Base to Accelerate Growth


EQS-News: MEDIQON Group AG / Key word(s): Corporate Action
MEDIQON Group AG: Expansion of Capital Base to Accelerate Growth

26.05.2023 / 08:55 CET/CEST
The issuer is solely responsible for the content of this announcement.


As announced in the ad-hoc release of May 26, 2023, MEDIQON Group AG has successfully completed a share capital increase and a bond placing of the 2020 perpetual bond.

Both transactions will raise circa EUR 16 million in additional funds for the Group. These proceeds will be invested to further accelerate the Group’s growth. Furthermore, the company intents to make repurchase offers for the entire outstanding amounts of the 2020 perpetual bond within two years financed from existing cash or, alternatively, by issuing shares at a price of at least EUR 18.00 per share.

Jan-Hendrik Mohr, CEO of MEDIQON Group AG commented:

"The platform companies of MEDIQON Group AG are growing in 2023 as well. Today, we are happy to announce the raising of additional funds to put our growth on a solid footing. We would like to thank our teams for the excellent and our shareholders and bondholders for the great trust in our work.“



26.05.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: MEDIQON Group AG
Herzog-Adolph-Strasse 2
61462 Königstein im Taunus
Germany
Phone: +49 (0) 6174-9687040
Fax: +49 (0) 6174-9687043
E-mail: ir@mediqon-group.de
Internet: www.mediqon-group.de
ISIN: DE0006618309, DE000A254TL0
WKN: 661830, A254TL
Listed: Regulated Unofficial Market in Berlin, Frankfurt (Basic Board), Stuttgart
EQS News ID: 1642503

 
End of News EQS News Service

1642503  26.05.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1642503&application_name=news&site_id=boersengefluester_html
Visual performance / price development - MEDIQON Group AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.